Keller Rohrback L.L.P. is investigating recent reports that OptumRx, UnitedHealthcare, and Cigna are forcing patients to overpay for prescriptions by charging a “clawback” on many commonly-used medications.
Keller Rohrback is delighted to report that this morning, Judge Charles Breyer granted final approval to the 2.0L class action TDI settlement.
Patients who are paying a co-pay at the pharmacy may in fact be paying the entirety of the prescription cost plus an additional kickback to their Pharmacy Benefits Manager (PBM).
According to a recent report by STAT news, “Mylan Pharmaceuticals has [begun] . . . a surreptitious lobbying campaign to have its [EpiPen] device added to a coveted list of preventive services that is maintained by the federal government.”
Keller Rohrback L.L.P., which over a year ago filed the first consumer class action lawsuit against Wells Fargo Bank, N.A. for opening unauthorized accounts, has begun investigating similar practices at other consumer banks.
